跳转至内容
Merck
CN

SML2473

Sigma-Aldrich

Pitavastatin calcium

≥98% (HPLC), HMG CoA reductase inhibitor, powder

别名:

(+)monocalcium bis{(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5dihydroxy-6-heptenoate}, (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid calcium salt

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C25H23FNO4 · 0.5Ca
化学文摘社编号:
147526-32-7
分子量:
440.49
UNSPSC代码:
51111800
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Pitavastatin calcium, ≥98% (HPLC)

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D +19 to +24°, c = 1 in acetonitrile: water (1:1)

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

[Ca+2].Fc5ccc(cc5)c6c7c(nc(c6\C=C\[C@@H](O)C[C@@H](O)CC(=O)[O-])C8CC8)cccc7.Fc1ccc(cc1)c2c3c(nc(c2\C=C\[C@@H](O)C[C@@H](O)CC(=O)[O-])C4CC4)cccc3

InChI

1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1

InChI key

RHGYHLPFVJEAOC-FFNUKLMVSA-L

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

HMG CoA reductase inhibitor
Pitavastatin calcium is a water-soluble inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Pitavastatin calcium is antilipidemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361f

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000480295
0000497494
0000497493
0000480295
0000497493

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sheridan M Hoy
American journal of cardiovascular drugs : drugs, devices, and other interventions, 17(2), 157-168 (2017-01-29)
Oral pitavastatin (Livalo®; Livazo®) is a competitive HMG-CoA reductase inhibitor that is available in the EU for the reduction of elevated total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels in adults with primary hypercholesterolemia and combined (mixed) dyslipidemia. In short-term
Jah Yeon Choi et al.
The American journal of cardiology, 122(6), 922-928 (2018-09-16)
Although statin use in patients with acute myocardial infarction (AMI) is mandatory, it has been suggested to be associated with new-onset diabetes mellitus (NODM). In real world practice, moderate-intensity statin therapy is more commonly used than high-intensity statin therapy. In

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持